Glykos Finland Oy | Date: 2014-04-14
The invention describes specific sialylated structures present on human stem cells and cell populations derived thereof. The invention is especially directed to methods to control the status of stem cells by observing changes in sialylation of the cells; and control of potential contaminations of biological materials; and reagents and methods used in connection with the cells in order to avoid alterations of the cell glycosylation by contaminating materials. The invention is further directed to novel stem cells, the glycosylation of which has been specifically altered.
Glykos Finland Oy and Novartis | Date: 2013-05-23
Glykos Finland Oy | Date: 2014-03-06
The invention describes methods for production of novel composition of glycans, glycomes, from human multipotent stem cells. The invention is further directed to methods for modifying the glycomes and analysis of the glycomes and the modified glycomes. Furthermore the invention is directed to stem cells carrying the modified glycomes on their surfaces.
Glykos Finland Oy | Date: 2014-05-02
The invention relates to a glycoprotein-toxic payload molecule conjugate, a toxic payload molecule-glycan conjugate, and a pharmaceutical composition. The invention further relates to a method for preparing the glycoprotein-toxic payload molecule conjugate, the method for modulating growth of a cell population and a method of treating tumour cells.
Glykos Finland Oy | Date: 2012-10-04
The present invention relates to a hematopoietic stem cell and/or a population thereof having a specific profile of cell surface proteins and/or proteoglycans. The present invention also relates to use of proteolytic enzymes, such as pronase and pronase-like enzymes in the modification of the cell surface of a hematopoietic stem cell. The present invention further relates to a method of modifying the cell surface of a hematopoietic stem cell by treatment with proteolytic enzymes, such as pronase and pronase-like enzymes.